Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Company Deals

Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Company Drug

Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China

Fineline Cube Feb 11, 2026
Company Drug

Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study

Fineline Cube Jan 9, 2023

China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...

Company Drug Policy / Regulatory

Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute

Fineline Cube Jan 9, 2023

The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...

Policy / Regulatory

China Strengthens COVID-19 Prevention and Control in Rural Areas

Fineline Cube Jan 9, 2023

China has intensified its COVID-19 prevention and control measures in rural areas, with the State...

Company Drug

Eli Lilly’s Donanemab Set to Gain Breakthrough Therapy Designation in China

Fineline Cube Jan 9, 2023

The Center for Drug Evaluation (CDE) website indicates that US-based Eli Lilly’s (NYSE: LLY) injectable...

Company Deals

Changzhou Sifary Medtech Secures Series B Funding for Global Expansion

Fineline Cube Jan 9, 2023

Changzhou Sifary Medical Technology Co., Ltd, a China-based platform for the globalization of oral medical...

Company Drug

Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA

Fineline Cube Jan 9, 2023

China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhifei Biological Products’ BCG Vaccine Filing Accepted by China’s NMPA

Fineline Cube Jan 9, 2023

China-based Chongqing Zhifei Biological Products Co., Ltd (SHE: 300122) has announced that its clinical trial...

Company Drug

Yantai Dongcheng Pharma Gets FDA Go-Ahead for 177Lu-LNC1004 Clinical Trial

Fineline Cube Jan 9, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

VivaVision Biotech Partners with Everads Therapy for Retinal Disease Therapies

Fineline Cube Jan 9, 2023

China’s VivaVision Biotech Inc. has announced a collaboration agreement with Israel-based Everads Therapy Ltd to...

Company Deals

Shenzhen-Based Rhegen Bio Raises RMB 100 Million in Pre-Series B Round

Fineline Cube Jan 9, 2023

Shenzhen-based biotechnology company Rhegen Bio, specializing in mRNA technology, has reportedly raised RMB 100 million...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Denmark

Fineline Cube Jan 9, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Jacobio Pharma Doses First Patient in US Phase I/IIa Study for JAB-2485

Fineline Cube Jan 9, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in...

Company Deals

VACSERA in Talks with Sinovac to Establish Integrated Vaccine Plant

Fineline Cube Jan 9, 2023

Egypt-based drug firm Holding Company for Biological Products and Vaccines (VACSERA) is reportedly in talks...

Company Drug

Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval

Fineline Cube Jan 9, 2023

Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...

Company Drug

Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study

Fineline Cube Jan 9, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...

Company Drug

Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials

Fineline Cube Jan 9, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...

Policy / Regulatory

China’s National Health Commission Releases Updated COVID-19 Treatment Plan

Fineline Cube Jan 9, 2023

The National Health Commission (NHC) has released the 10th edition of the national COVID-19 Diagnosis...

Company Drug

HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study

Fineline Cube Jan 6, 2023

On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...

Company Medical Device

Zai Lab and Novocure’s TTFields Device Shows Survival Benefit in Lung Cancer Study

Fineline Cube Jan 6, 2023

Shares in Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) and its partner Novocure...

Company Drug

Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133

Fineline Cube Jan 6, 2023

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...

Posts pagination

1 … 533 534 535 … 622

Recent updates

  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
  • Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics
  • Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Company Drug

Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China

Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.